圣地亚哥 - DexCom , Inc. (NASDAQ:DXCM) 公布的第二季度盈利和收入超过分析师预期,但股价下跌4%,因投资者似乎对公司业绩不太满意,尽管公司上调了全年指引。 这家连续血糖监测(CGM)技术提供商第二季度调整后每股收益为0.48美元,超过分析师预期的0.45美元。收入同比增长15%至11.6亿美元,超过了市场预期的11.2亿美元。 DexCom美国市场收入增长15%至...
Source Link圣地亚哥 - DexCom , Inc. (NASDAQ:DXCM) 公布的第二季度盈利和收入超过分析师预期,但股价下跌4%,因投资者似乎对公司业绩不太满意,尽管公司上调了全年指引。 这家连续血糖监测(CGM)技术提供商第二季度调整后每股收益为0.48美元,超过分析师预期的0.45美元。收入同比增长15%至11.6亿美元,超过了市场预期的11.2亿美元。 DexCom美国市场收入增长15%至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.